Krystal Biotech Q3 net loss $29.9M; B-VEC BLA with Priority Review accepted, PDUFA Feb 17, 2023

Krystal Biotech, Inc.

Cash and investments $407M at quarter end; net loss $29.9M ($1.17 per share) vs $15.6M loss in Q3 2021.
FDA accepted B-VEC BLA for dystrophic epidermolysis bullosa with Priority Review; PDUFA target Feb 17, 2023.
No Advisory Committee meeting or REMS needed after mid-cycle review; EMA Pediatric Committee gave positive opinion.
R&D spent $11.5M (Q3 2022); pipeline: KB407 (CF) IND accepted, dosing starts Q4 2022; KB105, KB104, KB301 advancing.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Krystal Biotech, Inc. reported the third quarter ended September 30, 2022 results: net income $29.9 million, EPS $(1.17) per common share (basic and diluted).

Period: the third quarter ended September 30, 2022
Net income: $29.9 million
EPS: $(1.17) per common share (basic and diluted)
Result: reported results

Exact text from the filing

Net losses for the quarters ended September 30, 2022 and 2021 were $29.9 million and $15.6 million, or $(1.17) and $(0.70), respectively, per common share (basic and diluted).

View on SEC.gov

Browse all earnings releases →

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-22-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.